MedTrace Logo

Fecal ESBL Resurgence During Antibiotic Treatment

NCT03206879 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-02-06

No results posted yet for this study

Summary

Norwegian hospitals are struggling to control spread of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) in health care settings. Strict screening and isolation criteria are enforced in hospital, and patients previously infected by ESBL-E are regarded as possible ESBL-E carriers indefinitely. This observational multi-centre cross-sectional study aims to estimate the duration of fecal ESBL-E carriage and to assess the risk of ESBL-E resurgence during hospital stay for patients previously infected by ESBL-E. Through better knowledge of these risk factors, infection control procedures may be better tailored to rhe individual patient.

Conditions

  • Antibiotic Drug Resistance

Sponsors & Collaborators

  • Sorlandet Hospital HF

    collaborator OTHER_GOV

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • Sykehuset Telemark

    collaborator OTHER_GOV

  • Oslo University Hospital

    collaborator OTHER

  • Sykehuset Ostfold

    collaborator OTHER

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Silje B Jørgensen, MD · Akershus univversitetssykehus HF

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-08-31
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03206879 on ClinicalTrials.gov